Repligen 'Very Confident' in Filtration Business Returning to Historical Growth Rates Next Year, RBC Says

11:39 AM EST, 11/02/2026 (MT Newswires) -- Repligen (RGEN) management are "very confident" that the company's Filtration business can return to historical growth rates in 2027, RBC Capital Markets analysts said in a Sunday note. A stronger bioprocess market and the diversity of Repligen's growth drivers will likely enable a return to mid-teens organic sales growth, analysts said. RBC said the Chromatography franchise's growth is accelerating, noting that the company sounded constructive on the opportunity. "With bioprocess end market tailwinds at its back and a specific gene therapy customer headwind set to lap in 2027, we see a compelling and diversified growth profile capable of driving a return to mid-teens sales growth," analysts said. RBC maintained an outperform rating and a $200 price target. Shares of the company were down 1.3% in Monday trading. Price: 174.51, Change: -2.43, Percent Change: -1.37